Oxycodone and Vicodin are not the same drug, though both are prescription opioid painkillers frequently used for moderate to severe pain. Oxycodone is a single opioid ingredient that appears in several brand-name products, while Vicodin is a brand name for a combination of a different opioid, hydrocodone, paired with acetaminophen. The confusion is understandable because both drugs land in the same pharmacological neighborhood, but the differences in their chemistry, side effects, abuse potential, and how your body processes them are real and sometimes clinically meaningful.
What Is Actually in Each Drug
Vicodin contains two active ingredients: hydrocodone (an opioid) and acetaminophen (the same over-the-counter pain reliever found in Tylenol). It comes in fixed-dose tablets where the hydrocodone component is typically 5 or 10 mg alongside 300 mg of acetaminophen. Generic hydrocodone-acetaminophen tablets are functionally the same product.
Oxycodone, by contrast, is the opioid itself. It can be prescribed on its own as an immediate-release tablet (generic oxycodone) or in an extended-release form (OxyContin). It also appears in combination products that pair it with acetaminophen, sold under brand names like Percocet. So when people ask whether oxycodone and Vicodin are the same, part of the muddle comes from the fact that both can be combined with acetaminophen, which makes them look similar on the surface. The core difference is the opioid: hydrocodone in one, oxycodone in the other.
The acetaminophen component matters on its own terms. When someone takes escalating doses of Vicodin or Percocet to manage worsening pain, the acetaminophen dose climbs alongside the opioid dose. Acetaminophen overdose can cause severe liver damage, and case reports document toxicity even in patients whose liver enzymes initially appear normal.1Wolters Kluwer Health / ACG Case Reports Journal. Severe Acetaminophen Toxicity From the Use of Oxycodone-Acetaminophen With Normal Liver Function Tests and a Completely Asymptomatic Course of Hospitalization This risk applies equally to any combination product containing acetaminophen, but it is the reason doctors sometimes prescribe oxycodone alone rather than pairing it with acetaminophen when higher opioid doses are anticipated.
How the Two Opioids Differ in Strength
Both oxycodone and hydrocodone are classified as mu-opioid receptor agonists, meaning they relieve pain by binding to the same type of receptor in the brain and spinal cord. In laboratory binding studies, the two drugs fall into the same intermediate-affinity group, with binding constants between 1 and 100 nanomolar, alongside morphine and methadone.2PubMed. Uniform assessment and ranking of opioid μ receptor binding constants for selected opioid drugs In practical terms, oxycodone is roughly equipotent to or slightly more potent than hydrocodone at comparable doses.3PubMed Central. The Relative Abuse Liability of Oral Oxycodone, Hydrocodone and Hydromorphone Assessed in Prescription Opioid Abusers
That slight potency edge shows up in controlled comparisons. In a study giving equal 10-mg doses of each opioid (combined with acetaminophen), oxycodone produced a broader range of measurable subjective effects and greater pupil constriction than hydrocodone, though both impaired psychomotor performance to a similar degree.4PubMed. Subjective, psychomotor, and physiological effects profile of hydrocodone/acetaminophen and oxycodone/acetaminophen combination products For most prescribing purposes, the two are treated as close enough in strength that milligram-for-milligram conversions hover near 1:1, with oxycodone sometimes given at slightly lower doses.
Do They Work Equally Well for Pain
For acute pain, the clinical picture is surprisingly even. A double-blind randomized trial comparing the two drugs in emergency department patients with fractures found no meaningful difference in pain relief at either 30 or 60 minutes.5PubMed. Comparison of oxycodone and hydrocodone for the treatment of acute pain associated with fractures: a double-blind, randomized, controlled trial Both groups improved significantly from baseline, and the confidence intervals for the between-group differences overlapped zero. If you showed up to an ER with a broken arm, you would get similar relief from either drug.
The story gets more nuanced in surgical recovery. A large study of patients undergoing hip or knee replacement found that those prescribed hydrocodone actually had modestly lower composite pain scores and consumed considerably fewer total opioid milligrams during recovery than those given oxycodone.6JAMA Network Open. Hydrocodone vs Oxycodone and Postoperative Pain and Opioid Use in Joint Arthroplasty The difference in pain scores was small, but the gap in total opioid consumption was striking. This suggests that in some postoperative contexts, hydrocodone may achieve equivalent or better comfort with a lower total opioid load, although the reasons for that pattern are not entirely settled.
Different Side Effect Profiles
Both drugs share the classic opioid side effects: nausea, constipation, drowsiness, and vomiting. But the balance shifts depending on which one you take. A comprehensive analysis using a large side-effect database found that oxycodone was particularly associated with drowsiness, while morphine and hydromorphone were more strongly linked to constipation.7PubMed Central. Comprehensive Analysis of Strong Opioid Side Effects in Palliative Care Using the SIDER Database
Oxycodone also appears to carry a higher per-dose risk of gastrointestinal side effects when compared head-to-head with newer opioids. Pharmacokinetic modeling has shown that the risk of nausea, vomiting, and constipation rises substantially with oxycodone exposure, more steeply than with some alternative analgesics at equivalent pain-relieving doses.8PubMed. Pharmacokinetic and pharmacodynamic modeling of opioid-induced gastrointestinal side effects in patients receiving tapentadol IR and oxycodone IR Hydrocodone tends to be somewhat better tolerated in the gut for many patients, which is one reason it has historically been the more commonly prescribed of the two for routine pain.
For either drug, the constipation issue is not trivial. Opioid-induced constipation persists for as long as the drug is taken and does not improve with time the way nausea often does. It is one of the leading reasons patients ask to switch medications or stop opioid therapy altogether.
Why Your Genetics Can Change Which One Works Better
Both hydrocodone and oxycodone are metabolized in the liver, but they rely on overlapping yet distinct enzyme pathways, and this has practical consequences. Hydrocodone is converted into its active metabolite, hydromorphone, primarily by the enzyme CYP2D6, while a second pathway through CYP3A4 produces an inactive metabolite. Oxycodone is also processed by CYP2D6 into an active metabolite, oxymorphone, but a larger share of its pain relief comes from the parent drug itself rather than from this metabolite.9Drug Metabolism and Disposition. Hydrocodone, Oxycodone, and Morphine Metabolism and Drug–Drug Interactions
This enzyme distinction has a real-world implication. If you are taking other medications that block CYP2D6, like certain antidepressants, antihistamines, or heart medications, those drugs can significantly reduce how well hydrocodone works. In one emergency department study, patients who were also taking CYP2D6-blocking medications were only about a third as likely to get meaningful pain relief from hydrocodone. Oxycodone effectiveness, on the other hand, was not significantly changed by CYP2D6 drug interactions.10Academic Emergency Medicine. The Effect of CYP2D6 Drug-Drug Interactions on Hydrocodone Effectiveness For anyone on a complex medication regimen, this is exactly the kind of difference that can make one drug the right choice and the other a poor one.
Genetic variation in CYP2D6 activity itself adds another layer. A small percentage of the population are “poor metabolizers” who produce very little functional CYP2D6 enzyme. These individuals may get inadequate relief from hydrocodone because they cannot convert it efficiently to hydromorphone. They would generally do better on oxycodone, which does not depend as heavily on that single enzyme for its pain-relieving effect.
Abuse Potential and Scheduling
Until 2014, hydrocodone combination products like Vicodin were classified as Schedule III controlled substances in the United States, while oxycodone in all forms was Schedule II. Schedule II drugs face tighter restrictions: no refills, no phone-in prescriptions, and stricter limits on quantities. The practical result was that Vicodin was far easier to prescribe and obtain than oxycodone.
The scheduling gap always sat uneasily with the pharmacology. Studies of the two drugs’ abuse liability in experienced opioid users have consistently found them to be similar in subjective effects like liking, euphoria, and desire to take the drug again.3PubMed Central. The Relative Abuse Liability of Oral Oxycodone, Hydrocodone and Hydromorphone Assessed in Prescription Opioid Abusers If anything, oxycodone shows higher “likability” scores and fewer negative subjective effects, which may make it slightly more attractive for misuse.11PubMed Central. Likeability and Abuse Liability of Commonly Prescribed Opioids Among people entering substance abuse treatment who reported a preferred opioid, oxycodone was chosen by a larger share than hydrocodone, with users frequently citing the quality of the high as a deciding factor.12PubMed Central. Factors influencing the selection of hydrocodone and oxycodone as primary opioids in substance abusers seeking treatment in the United States
In October 2014, the DEA rescheduled hydrocodone combination products to Schedule II, closing the regulatory gap. The effect was dramatic. In the year following the change, dispensed hydrocodone combination prescriptions dropped by about 22%, with refills accounting for nearly three-quarters of that decline.13JAMA Internal Medicine. Effect of US Drug Enforcement Administration’s Rescheduling of Hydrocodone Combination Analgesic Products on Opioid Analgesic Prescribing State-level data from Ohio showed a similar pattern, with an immediate drop and a continued monthly decline, though codeine prescriptions temporarily rose, suggesting some doctors simply switched to a less-restricted opioid.14PubMed Central. Effects of Rescheduling Hydrocodone on Opioid Prescribing in Ohio Today both drugs sit in the same schedule, and the prescribing burdens are identical.
Long-Term Use Patterns
One less obvious difference is how often short-term prescriptions turn into chronic use. A primary care study tracking patients who were initially prescribed one of the two drugs found a surprisingly large gap: roughly 12% of hydrocodone patients transitioned to long-term opioid use, compared to about 2% of oxycodone patients. Among those who received more than one prescription, the rates climbed to about 23% for hydrocodone versus 5% for oxycodone.15PubMed Central. Long-term use of hydrocodone vs. oxycodone in primary care
That finding may seem counterintuitive, since oxycodone is often perceived as the “stronger” or “more dangerous” drug. The likely explanation has less to do with the pharmacology of the drugs themselves and more with prescribing context. Because hydrocodone was historically easier to prescribe (Schedule III before 2014), it was the default first-line opioid in many primary care offices. Patients received it for milder complaints and with less gatekeeping around refills, creating more opportunities for use to become habitual. Oxycodone, carrying Schedule II restrictions and a reputation for higher potency, was prescribed more cautiously from the start. The drug itself did not create the difference in long-term use rates. The system around it did.
Using Either Drug in Kidney Disease and Older Adults
Both oxycodone and hydrocodone, along with their active metabolites, are cleared through the kidneys, which makes dose adjustments critical for people with impaired kidney function. In older adults with chronic kidney disease, both drugs are considered acceptable options but require careful monitoring and should be started at the lowest possible dose, typically 2.5 to 5 mg every four to six hours.16PubMed Central. Opioid Management in Older Adults with Chronic Kidney Disease: A Review The active metabolites of both drugs can accumulate when the kidneys are not clearing them efficiently, potentially increasing sedation and respiratory depression.
Neither drug is clearly safer than the other in this population. The choice often comes down to what other medications the patient is taking (given the CYP2D6 interaction issue discussed earlier), how well the kidneys are functioning, and how closely the patient can be monitored. For patients on dialysis, both drugs require extra caution, and some clinicians prefer hydrocodone simply because it has a longer track record in that specific setting.
Abuse-Deterrent Formulations
One area where oxycodone has a technological lead is in abuse-deterrent product design. Extended-release oxycodone (OxyContin) was reformulated in 2010 using a technology that makes the tablet difficult to crush and turns it into a gummy mass if dissolved in liquid, which makes it harder to snort or inject. A newer extended-release oxycodone product, Xtampza ER, uses a different approach that maintains its extended-release properties even when the capsule contents are chewed or crushed, making it the only extended-release opioid without a boxed warning against those forms of manipulation.17PubMed Central. Review of Opioid Abuse-Deterrent Formulations: Impact and Barriers to Access These formulations have been shown to reduce rates of abuse and diversion, though they are not foolproof and they do not prevent someone from simply taking more pills orally than prescribed.18PubMed Central. Motivations, perceived risk, and tampering of XTAMPZA ER and abuse-deterrent opioid drugs
No abuse-deterrent formulation of hydrocodone has gained comparable traction in the market. Extended-release hydrocodone (brand name Zohydro ER and later Vantrela ER) exists, but the product landscape is smaller and less developed. For patients or prescribers specifically concerned about tampering risk with extended-release products, oxycodone currently offers more options.
Which One Gets Prescribed and Why
Despite their pharmacological similarities, oxycodone and hydrocodone end up in different clinical niches for reasons that are partly scientific and partly structural. Hydrocodone combination products remain among the most commonly prescribed opioids in outpatient primary care settings. Their long familiarity, generally mild side-effect profile, and the built-in ceiling effect of the acetaminophen component (which discourages extreme dose escalation) all contribute to their staying power.
Oxycodone tends to be the drug of choice when higher potency is needed, when extended-release formulations are appropriate, or when drug interactions with CYP2D6 make hydrocodone unreliable. It is also more commonly used in oncology and palliative care settings, where doses may need to escalate beyond what a combination product with acetaminophen can safely deliver.
Neither drug is categorically “better” or “worse.” The right one depends on the type and severity of pain, other medications in the mix, kidney function, the patient’s history with opioids, and how long the prescription is expected to last. Anyone who has been told the two drugs are interchangeable should know that while they overlap considerably, the differences are real enough to matter in specific clinical situations.